UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 949

Sortiert nach

Crizotinib Can Overcome Acquired Resistance to CH5424802: Is Amplification of the MET Gene a Key Factor?

Journal of thoracic oncology, 2014-03, Vol.9 (3), p.e27-e28

2014

Link zum Volltext

Verfügbarkeit prüfen

Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2020-01, Vol.139, p.195-199

2020

Link zum Volltext

Verfügbarkeit prüfen

Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study

European journal of cancer (1990), 2019-05, Vol.113, p.78-86

2019

Link zum Volltext

Verfügbarkeit prüfen

Vandetanib in patients with previously treated RET -rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial

The lancet respiratory medicine, 2017-01, Vol.5 (1), p.42-50

2017

Link zum Volltext

Verfügbarkeit prüfen

CH5424802 (RO5424802) for patients with ALK -rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study

The lancet oncology, 2013-06, Vol.14 (7), p.590-598

2013

Link zum Volltext

Verfügbarkeit prüfen

Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non-Small-Cell Lung Cancer

Journal of clinical oncology, 2020-07, Vol.38 (19), p.2187-2196

2020

Link zum Volltext

Verfügbarkeit prüfen

The Role of Radiotherapy in the Treatment of Small-Cell Lung Cancer

Current Treatment Options in Oncology, 2015-12, Vol.16 (12), p.56, Article 56

2015

Link zum Volltext

Verfügbarkeit prüfen

Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort

Lung cancer (Amsterdam, Netherlands), 2018-03, Vol.117, p.14-19

2018

Link zum Volltext

Verfügbarkeit prüfen

KEYNOTE‐025: Phase 1b study of pembrolizumab in Japanese patients with previously treated programmed death ligand 1–positive advanced non–small‐cell lung cancer

Cancer science, 2019-03, Vol.110 (3), p.1012-1020

2019

Link zum Volltext

Verfügbarkeit prüfen

Capmatinib in Japanese patients with MET exon 14 skipping–mutated or MET‐amplified advanced NSCLC: GEOMETRY mono‐1 study

Cancer science, 2021-04, Vol.112 (4), p.1556-1566

2021

Link zum Volltext

Verfügbarkeit prüfen

Phase III Study Comparing Second- and Third-Generation Regimens With Concurrent Thoracic Radiotherapy in Patients With Unresectable Stage III Non–Small-Cell Lung Cancer: West Japan Thoracic Oncology Group WJTOG0105

Journal of clinical oncology, 2010-08, Vol.28 (23), p.3739-3745

2010

Link zum Volltext

Verfügbarkeit prüfen

Identification of the Best Prognostic Marker Among Immunonutritional Parameters Using Serum C-Reactive Protein and Albumin in Non-Small Cell Lung Cancer

Annals of surgical oncology, 2021-06, Vol.28 (6), p.3046-3054

2021

Link zum Volltext

Verfügbarkeit prüfen

Spotlight on lorlatinib and its potential in the treatment of NSCLC: the evidence to date

OncoTargets and therapy, 2018-01, Vol.11, p.5093-5101

2018

Link zum Volltext

Verfügbarkeit prüfen

Three-Year Follow-Up of an Alectinib Phase I/II Study in ALK-Positive Non-Small-Cell Lung Cancer: AF-001JP

Journal of clinical oncology, 2017-05, Vol.35 (14), p.1515-1521

2017

Link zum Volltext

Verfügbarkeit prüfen

Co-expression of IDO1 and PD-L1 in lung squamous cell carcinoma: Potential targets of novel combination therapy

Lung cancer (Amsterdam, Netherlands), 2019-02, Vol.128, p.26-32

2019

Link zum Volltext

Verfügbarkeit prüfen

Predictive Factors for Interstitial Lung Disease, Antitumor Response, and Survival in Non–Small-Cell Lung Cancer Patients Treated With Gefitinib

Journal of clinical oncology, 2006-06, Vol.24 (16), p.2549-2556

2006

Link zum Volltext

Verfügbarkeit prüfen

Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patients

Japanese journal of clinical oncology, 2016-05, Vol.46 (5), p.462-467

2016

Link zum Volltext

Verfügbarkeit prüfen

Dual effects of reversed winter–spring temperatures on year‐to‐year variation in the recruitment of chub mackerel (Scomber japonicus)

Fisheries oceanography, 2019-03, Vol.28 (2), p.212-227

2019

Link zum Volltext

Verfügbarkeit prüfen

Secondary Mutations at I1171 in the ALK Gene Confer Resistance to Both Crizotinib and Alectinib

Journal of thoracic oncology, 2014-12, Vol.9 (12), p.e86-e87

2014

Link zum Volltext

Verfügbarkeit prüfen

Survival benefit of using pemetrexed for EGFR mutation-positive advanced non-small-cell lung cancer in a randomized phase III study comparing gefitinib to cisplatin plus docetaxel (WJTOG3405)

International journal of clinical oncology, 2022-09, Vol.27 (9), p.1404-1412

2022

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 949

Suche als RSS-Feed

Aktive Filter

ThemaPatients

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(728)
Mit Volltextzugriff
(905)

Publikationsform

Sprache

Englisch
(825)
Japanisch
(335)
Deutsch
(4)
Koreanisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(474)
Life Sciences & Biomedicine
(377)
Humans
(294)
Male
(206)
Female
(182)
Oncology
(177)
Middle Aged
(163)
Aged
(154)
Adult
(132)
Biological And Medical Sciences
(92)
Lung Neoplasms - Drug Therapy
(91)
Physical Sciences
(80)
Medical Sciences
(74)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(72)
Respiratory System
(67)
Aged, 80 And Over
(63)
Lung Neoplasms - Pathology
(62)
Surgery
(62)
Treatment Outcome
(56)
Medicine
(55)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial

Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study

Crizotinib Can Overcome Acquired Resistance to CH5424802: Is Amplification of the MET Gene a Key Factor?

Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer

Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study

Vandetanib in patients with previously treated RET -rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial

CH5424802 (RO5424802) for patients with ALK -rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study

Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non-Small-Cell Lung Cancer

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

The Role of Radiotherapy in the Treatment of Small-Cell Lung Cancer

Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort

Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial

KEYNOTE‐025: Phase 1b study of pembrolizumab in Japanese patients with previously treated programmed death ligand 1–positive advanced non–small‐cell lung cancer

Capmatinib in Japanese patients with MET exon 14 skipping–mutated or MET‐amplified advanced NSCLC: GEOMETRY mono‐1 study

Phase III Study Comparing Second- and Third-Generation Regimens With Concurrent Thoracic Radiotherapy in Patients With Unresectable Stage III Non–Small-Cell Lung Cancer: West Japan Thoracic Oncology Group WJTOG0105

Identification of the Best Prognostic Marker Among Immunonutritional Parameters Using Serum C-Reactive Protein and Albumin in Non-Small Cell Lung Cancer

Spotlight on lorlatinib and its potential in the treatment of NSCLC: the evidence to date

Three-Year Follow-Up of an Alectinib Phase I/II Study in ALK-Positive Non-Small-Cell Lung Cancer: AF-001JP

Co-expression of IDO1 and PD-L1 in lung squamous cell carcinoma: Potential targets of novel combination therapy

Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial

Predictive Factors for Interstitial Lung Disease, Antitumor Response, and Survival in Non–Small-Cell Lung Cancer Patients Treated With Gefitinib

Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patients

Dual effects of reversed winter–spring temperatures on year‐to‐year variation in the recruitment of chub mackerel (Scomber japonicus)

Secondary Mutations at I1171 in the ALK Gene Confer Resistance to Both Crizotinib and Alectinib

Survival benefit of using pemetrexed for EGFR mutation-positive advanced non-small-cell lung cancer in a randomized phase III study comparing gefitinib to cisplatin plus docetaxel (WJTOG3405)

Aktive Filter

Suchergebnisse filtern